X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1106) 1106
Publication (83) 83
Book Chapter (14) 14
Book Review (10) 10
Data Set (1) 1
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (989) 989
male (704) 704
female (701) 701
child (652) 652
child, preschool (540) 540
adolescent (533) 533
rhabdomyosarcoma - mortality (498) 498
rhabdomyosarcoma (483) 483
oncology (409) 409
infant (397) 397
index medicus (374) 374
adult (344) 344
prognosis (342) 342
rhabdomyosarcoma - pathology (291) 291
rhabdomyosarcoma - therapy (286) 286
children (260) 260
survival rate (259) 259
pediatrics (255) 255
retrospective studies (249) 249
combined modality therapy (218) 218
cancer (205) 205
surgery (201) 201
chemotherapy (200) 200
middle aged (179) 179
intergroup rhabdomyosarcoma (176) 176
tumors (173) 173
rhabdomyosarcoma - surgery (170) 170
treatment outcome (168) 168
sarcoma (164) 164
follow-up studies (158) 158
neoplasm staging (158) 158
aged (145) 145
disease-free survival (145) 145
antineoplastic combined chemotherapy protocols - therapeutic use (138) 138
rhabdomyosarcoma - drug therapy (135) 135
sarcoma - mortality (127) 127
survival analysis (117) 117
childhood (111) 111
radiotherapy (109) 109
hematology (104) 104
rhabdomyosarcoma - diagnosis (104) 104
soft tissue neoplasms - mortality (104) 104
young adult (103) 103
infant, newborn (100) 100
survival (97) 97
care and treatment (93) 93
rhabdomyosarcoma - radiotherapy (93) 93
age factors (86) 86
diagnosis (86) 86
sarcoma - pathology (83) 83
time factors (80) 80
soft-tissue sarcoma (79) 79
pathology (78) 78
research (78) 78
neoplasm metastasis (76) 76
therapy (73) 73
animals (71) 71
head and neck neoplasms - mortality (70) 70
metastasis (69) 69
analysis (68) 68
soft tissue neoplasms - pathology (68) 68
neoplasm recurrence, local (67) 67
embryonal rhabdomyosarcoma (66) 66
sarcoma - therapy (63) 63
patients (62) 62
risk factors (61) 61
alveolar rhabdomyosarcoma (60) 60
kaplan-meier estimate (59) 59
soft-tissue sarcomas (59) 59
health aspects (58) 58
immunohistochemistry (55) 55
radiology, nuclear medicine & medical imaging (55) 55
experience (54) 54
mortality (53) 53
childhood rhabdomyosarcoma (52) 52
prognostic-factors (52) 52
radiotherapy dosage (52) 52
rhabdomyosarcoma - genetics (51) 51
rhabdomyosarcoma, embryonal - mortality (51) 51
head and neck neoplasms - therapy (50) 50
medical prognosis (50) 50
aged, 80 and over (49) 49
childrens oncology group (49) 49
management (49) 49
radiation therapy (48) 48
adolescents (47) 47
expression (47) 47
neoplasm recurrence, local - mortality (47) 47
sarcoma - surgery (47) 47
multivariate analysis (46) 46
sarcomas (45) 45
rhabdomyosarcoma, alveolar - mortality (44) 44
chemotherapy, adjuvant (43) 43
medicine (43) 43
proportional hazards models (43) 43
ewings-sarcoma (42) 42
mice (42) 42
rhabdomyosarcoma - epidemiology (42) 42
article (41) 41
rhabdomyosarcoma, alveolar - pathology (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1048) 1048
German (20) 20
French (14) 14
Spanish (9) 9
Chinese (8) 8
Russian (8) 8
Japanese (5) 5
Italian (4) 4
Polish (4) 4
Croatian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2016, Volume 67, pp. 130 - 140
Abstract Objectives Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise... 
Hematology, Oncology and Palliative Medicine | Innovative Therapies for Children with Cancer | Dose-finding trial | Prognostic factor | Phase I trial | Children | Adolescents | Survival | ONCOLOGY TRIALS | SCORE | VALIDATION | I CLINICAL-TRIALS | CONTEXT | PEDIATRIC PHASE-I | CENTER EXPERIENCE | ONCOLOGY | Osteosarcoma - drug therapy | Multivariate Analysis | Prognosis | Neuroectodermal Tumors, Primitive - drug therapy | Humans | Child, Preschool | Infant | Male | Neuroblastoma - mortality | Sarcoma, Ewing - mortality | Medulloblastoma - mortality | Ependymoma - drug therapy | Employment | Ependymoma - mortality | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Retrospective Studies | Child | Rhabdomyosarcoma - mortality | Schools | Osteosarcoma - mortality | Glioma - mortality | Neuroectodermal Tumors, Primitive - mortality | Europe | Proportional Hazards Models | Neoplasms - mortality | Therapies, Investigational | Survival Rate | Sarcoma - drug therapy | Neoplasms - drug therapy | Sarcoma, Ewing - drug therapy | Neuroblastoma - drug therapy | Adolescent | Medulloblastoma - drug therapy | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Clinical Trials, Phase I as Topic | Glioma - drug therapy | Care and treatment | Patient outcomes | Children's hospitals | Oncology, Experimental | Clinical trials | Research | Health aspects | Cancer
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2018, Volume 41, Issue 5, pp. 471 - 475
Journal Article
International Journal of Radiation Oncology Biology Physics, ISSN 0360-3016, 04/2012, Volume 82, Issue 5, pp. 1764 - 1770
Purpose: To compare the dosimetric parameters of intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) in patients with... 
Intensity-modulated radiotherapy | 3D-CRT | IMRT | Three-dimensional conformal radiotherapy | Rhabdomyosarcoma | Intermediate risk | TISSUE | CANCER | RADIATION-THERAPY | TRIAL | ONCOLOGY | NECK-RHABDOMYOSARCOMA | CARCINOMA | SURVIVORS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Organs at Risk - radiation effects | Humans | Rhabdomyosarcoma - pathology | Male | Radiotherapy, Intensity-Modulated - adverse effects | Rhabdomyosarcoma - radiotherapy | Rhabdomyosarcoma, Alveolar - mortality | Treatment Failure | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Rhabdomyosarcoma, Alveolar - pathology | Child | Rhabdomyosarcoma - mortality | Sarcoma - radiotherapy | Rhabdomyosarcoma, Embryonal - pathology | Radiotherapy, Intensity-Modulated - mortality | Rhabdomyosarcoma, Alveolar - drug therapy | Radiotherapy, Intensity-Modulated - methods | Rhabdomyosarcoma, Alveolar - radiotherapy | Rhabdomyosarcoma, Embryonal - mortality | Rhabdomyosarcoma, Embryonal - drug therapy | Sarcoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epidemiologic Methods | Radiotherapy, Conformal - mortality | Radiotherapy, Conformal - adverse effects | Rhabdomyosarcoma, Embryonal - radiotherapy | Radiotherapy, Conformal - methods | Nuclear radiation | Analysis | Radiation | Medical care | Universities and colleges | Radiotherapy | Methods | Quality management | Index Medicus | PATIENTS | NEOPLASMS | INTEGRAL DOSES | FAILURES | TOXICITY | COMPARATIVE EVALUATIONS | CHILDREN | PLANNING | MULTIVARIATE ANALYSIS | RADIOLOGY AND NUCLEAR MEDICINE | REGRESSION ANALYSIS | RADIOTHERAPY | CONTROL | HAZARDS
Journal Article
Pediatric Blood and Cancer, ISSN 1545-5009, 06/2011, Volume 56, Issue 6, pp. 994 - 1002
Disparities in cancer burden by race/ ethnicity have been reported, primarily in adults with cancer. However, there appear to be gaps in the pediatric oncology... 
Survivorship | Survival | Childhood cancer | Health disparities | ETHNIC-DIFFERENCES | survivorship | S-METHYLTRANSFERASE GENE | ONCOLOGY-GROUP | survival | ACUTE MYELOID-LEUKEMIA | WHITE-CHILDREN | CHILDHOOD-CANCER | health disparities | MERCAPTOPURINE METABOLISM | ONCOLOGY | RISK NEUROBLASTOMA | ACUTE LYMPHOBLASTIC-LEUKEMIA | PEDIATRIC-PATIENTS | PEDIATRICS | childhood cancer | HEMATOLOGY | Rhabdomyosarcoma - ethnology | Asian Americans - statistics & numerical data | Humans | Neuroblastoma - ethnology | Hispanic Americans - statistics & numerical data | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Neuroblastoma - mortality | Neuroblastoma - therapy | Neoplasms - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Neoplasms - ethnology | Antineoplastic Agents - adverse effects | Health Services Accessibility | Hodgkin Disease - mortality | Child | Leukemia, Myeloid, Acute - ethnology | Rhabdomyosarcoma - mortality | Leukemia, Myeloid, Acute - therapy | Pharmacogenetics | SEER Program | Neoplasms - mortality | European Continental Ancestry Group - statistics & numerical data | Survival Rate | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | African Americans - statistics & numerical data | Precursor Cell Lymphoblastic Leukemia-Lymphoma - ethnology | Hodgkin Disease - therapy | Hodgkin Disease - ethnology | Rhabdomyosarcoma - therapy | Index Medicus | Health Disparities | Childhood Cancer
Journal Article
Modern Pathology, ISSN 0893-3952, 09/2008, Volume 21, Issue 9, pp. 1084 - 1094
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 2, pp. 635 - 642
Purpose To report the clinical outcome and late side effect profile of proton radiotherapy in the treatment of children with parameningeal rhabdomyosarcoma... 
Radiology | Hematology, Oncology and Palliative Medicine | Conformal radiotherapy | Late effects | Proton radiotherapy | Parameningeal rhabdomyosarcoma | Pediatric | NECK RHABDOMYOSARCOMA | HEAD | INTERGROUP RHABDOMYOSARCOMA | INTERNATIONAL-SOCIETY | INTENSITY-MODULATED RADIOTHERAPY | NONMETASTATIC RHABDOMYOSARCOMA | SOFT-TISSUE | CHILDREN | CHILDHOOD-CANCER | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PEDIATRIC-ONCOLOGY | Follow-Up Studies | Protons - adverse effects | Humans | Child, Preschool | Protons - therapeutic use | Infant | Male | Radiotherapy - adverse effects | Organ Sparing Treatments - methods | Rhabdomyosarcoma - radiotherapy | Meningeal Neoplasms - drug therapy | Rhabdomyosarcoma, Alveolar - mortality | Massachusetts | Female | Rhabdomyosarcoma - drug therapy | Child | Rhabdomyosarcoma - mortality | Rhabdomyosarcoma, Alveolar - drug therapy | Rhabdomyosarcoma, Alveolar - radiotherapy | Treatment Outcome | Rhabdomyosarcoma, Embryonal - mortality | Rhabdomyosarcoma, Embryonal - drug therapy | Meningeal Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Meningeal Neoplasms - radiotherapy | Rhabdomyosarcoma, Embryonal - radiotherapy | Radiotherapy | Medical colleges | Nuclear radiation | DIAGNOSIS | PATIENTS | NEOPLASMS | FAILURES | PHOTONS | TEETH | RADIATION DOSES | CARIES | HISTOLOGY | PROTONS | SINUSES | MEDICAL RECORDS | NOSE | RADIATION DOSE UNITS | RADIOLOGY AND NUCLEAR MEDICINE | PEDIATRICS | RADIOTHERAPY | SIDE EFFECTS | COBALT | CONTROL
Journal Article
BMC Research Notes, ISSN 1756-0500, 09/2015, Volume 8, Issue 1, p. 474
Journal Article
Oncology, ISSN 0030-2414, 06/2011, Volume 80, Issue 1-2, pp. 21 - 28
Objective: Pediatric-type sarcomas such as Ewing’s sarcoma (EWS)/primitive neuroectodermal tumor family and rhabdomyosarcoma are relatively uncommon in adult... 
Clinical Study | Primitive neuroectodermal tumor family | Prognosis | Desmoplastic small round-cell tumor | Ewing's sarcoma | Pediatric-type sarcoma | Rhabdomyosarcoma | EWINGS-SARCOMA | ONCOLOGY-GROUP | INTERGROUP-RHABDOMYOSARCOMA | IFOSFAMIDE | CHILDHOOD | CHEMOTHERAPY | PRIMITIVE NEUROECTODERMAL TUMOR | ETOPOSIDE | RHABDOMYOSARCOMA-STUDY-IV | ONCOLOGY | EXPERIENCE | Bone Neoplasms - mortality | Multivariate Analysis | Age Factors | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Middle Aged | Brain Neoplasms - pathology | Sarcoma, Ewing - pathology | Desmoplastic Small Round Cell Tumor - mortality | Rhabdomyosarcoma - pathology | Male | Sarcoma, Ewing - mortality | Bone Neoplasms - pathology | Prostatic Neoplasms - therapy | Young Adult | Desmoplastic Small Round Cell Tumor - pathology | Urinary Bladder Neoplasms - pathology | Adult | Desmoplastic Small Round Cell Tumor - therapy | Female | Retrospective Studies | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Rhabdomyosarcoma - mortality | Prostatic Neoplasms - pathology | Urinary Bladder Neoplasms - mortality | Neuroectodermal Tumors, Primitive - mortality | Head and Neck Neoplasms - therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Neuroectodermal Tumors, Primitive - therapy | Prostatic Neoplasms - mortality | Head and Neck Neoplasms - pathology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urinary Bladder Neoplasms - therapy | Adolescent | Brain Neoplasms - therapy | Aged | Head and Neck Neoplasms - mortality | Rhabdomyosarcoma - therapy | Neuroectodermal Tumors, Primitive - pathology | Medical prognosis | Cancer
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3807 - 3815
This is the first study to systematically interrogate programmed death‐ligand 1 expression in a large series of pediatric cancers. A high frequency of the... 
checkpoint | neuroblastoma | tumor‐infiltrating lymphocytes | programmed death 1/programmed death 1 ligand (PD‐1/PD‐L1) blockade | immunotherapy | pediatric cancer | tumor-infiltrating lymphocytes | programmed death 1/programmed death 1 ligand (PD-1/PD-L1) blockade | ONCOLOGY-GROUP | PD-L1 EXPRESSION | INFILTRATING LYMPHOCYTES | WILMS-TUMOR | UNTREATED MELANOMA | LUNG-CANCER | ONCOLOGY | NEUROECTODERMAL TUMOR | ADULT GLIOBLASTOMA | T-CELLS | CLINICAL-SIGNIFICANCE | Immunohistochemistry | Bone Neoplasms - mortality | Tissue Array Analysis | Humans | Sarcoma, Ewing - pathology | Rhabdomyosarcoma - pathology | Neuroblastoma - mortality | Osteosarcoma - chemistry | Macrophages | Bone Neoplasms - pathology | Burkitt Lymphoma - pathology | Neoplasms - chemistry | Lymphocytes, Tumor-Infiltrating | Burkitt Lymphoma - immunology | Neuroblastoma - immunology | Bone Neoplasms - chemistry | Glioblastoma - chemistry | Child | Neuroblastoma - pathology | Rhabdomyosarcoma - immunology | Sarcoma, Ewing - chemistry | Neuroblastoma - chemistry | Neoplasms - mortality | Bone Neoplasms - immunology | Burkitt Lymphoma - chemistry | Sarcoma, Ewing - immunology | Osteosarcoma - immunology | Glioblastoma - immunology | Neoplasms - immunology | Glioblastoma - pathology | Neoplasm Proteins - analysis | B7-H1 Antigen - analysis | Rhabdomyosarcoma - chemistry | Neoplasms - pathology | Osteosarcoma - pathology | Chemotherapy | Usage | Care and treatment | Diagnosis | Research | Gene expression | Cancer in children | Cancer | Pediatrics | Parkinson's disease | PD-1 protein | Glioblastoma | Neuroblastoma | Tissues | Anticancer properties | Metastases | Lymphocytes | Bioindicators | Children | Movement disorders | Immune system | Immune response | Neurodegenerative diseases | Tumor cells | Mortality | Patients | Survival | Glioblastoma multiforme | Lymphoma | Burkitt's lymphoma | PD-L1 protein | Biomarkers | Ligands | Death | Antitumor activity | Infiltration | Lymphomas | Diagnostic systems | Tumors | Apoptosis
Journal Article